Bure Equity AB

Latest Results (14.01.2026):

This summary covers Bure Equity AB’s latest reported results for the fourth quarter of 2024 (Q4 2024) and the full year 2024. Bure closed 2024 with net asset value (NAV) per share SEK 333.0 (SEK 24,689M NAV), a 29.1% increase year‑on‑year, while NAV fell 5.0% during Q4 2024. Group earnings after tax for the year were SEK 5,735M and earnings per share were SEK 77.4. The Board proposes an ordinary dividend of SEK 2.75 per share; NAV was SEK 353.6 per share on 19 Feb 2025 (post‑period).

Net asset value (NAV)

NAV per share at 31 Dec 2024: SEK 333.0 (total NAV SEK 24,689M). NAV rose 29.1% vs 31 Dec 2023 (from SEK 257.9) but fell 5.0% during Q4 2024 (started quarter at SEK 350.3). Post‑period NAV: SEK 353.6 on 19 Feb 2025 (+6.2% since 1 Jan 2025).

Full‑year financial results (2024)

Group earnings after tax: SEK 5,735M (2023: 4,749). Earnings per share: SEK 77.4 (64.0). Total return on the Bure share in 2024: 34.5% (SIX Return Index +8.6%). Dividends received by the Group during 2024: reported SEK 208M.

Q4 2024 performance

Q4 2024 earnings from investment activities were negative (group level) driven by fair‑value changes: fair‑value changes on financial assets for Q4 were SEK ‑1,269M. Dividends in Q4 were small (SEK 8M). NAV per share decline in Q4 reflects listed portfolio price moves.

Portfolio drivers

Listed holdings made up ~85.6% of NAV at year end. Largest contributors and notable developments in 2024: Yubico (strong growth, share price +85% in 2024; sales +27% cited), Mycronic (record year; share price +39%; operating profit > SEK 2bn), Xvivo and Vitrolife (strong performance). Value increases in listed holdings totaled SEK 5,795M during 2024.

Cash, treasury and balance sheet

Group cash and cash equivalents reported: SEK 646M; total treasury assets (cash + short‑term investments/other) reported at SEK 738M at year‑end (≈3.0% of NAV, down from 8.1% at end‑2023). Group equity at 31 Dec 2024: SEK 24,688M (equity/assets ratio ~100%).

Corporate actions & investments

Notable transactions in 2024: acquisition of 14.5% of Mentimeter for SEK 531M; purchase of 700,000 Cavotec shares for SEK 12M; Bure Growth signed a SEK 17M convertible loan to BioLamina; Atle (group company) made several fund‑manager investments and acquired stakes (e.g., 66% of First Fondene AS).

Shareholder distribution & dividend

The Board proposes an ordinary dividend of SEK 2.75 per share (previous year SEK 2.50). Number of Bure shares outstanding noted in the report: 74,501,755 (of which 354,834 are Class C shares).

Post‑period note

After the reporting date the company published NAV per share SEK 353.6 on 19 Feb 2025 (an increase of 6.2% since the beginning of the year), indicating continued valuation movement in the portfolio after year‑end.